# US 2001/0036928 A1 · Heterologous boosting immunizations

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0036928 A1
- Document ID: US20010036928A1
- Status: Published application
- Kind: A1
- Application number: 09/838,987
- Filed: 2001-04-20
- Published: 2001-11-01
- Earliest claimed: 1996-04-22
- Inventors: Ronald S. Chamberlain; Kari R. Irvine; Steven A. Rosenberg; Nicholas P. Restifo
- Web page: https://patentgrep.com/patent/US20010036928A1

## CPC

- A61K 39/0011: {Cancer antigens}
- A61K 39/001156: {Tyrosinase and tyrosinase related proteinases [TRP-1 or TRP-2]}
- A61K 39/001191: {Melan-A/MART}
- A61K 39/001192: {Glycoprotein 100 [Gp100]}
- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61K 2039/53: {DNA (RNA) vaccination}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2039/57: {characterised by the type of response, e.g. Th1, Th2}
- C12N 2710/24143: viral genome or elements thereof as genetic vector
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

This invention describes methods of vaccination for the effective generation of an antigen-specific immune response. More particularly, this invention describes the use of heterologous vaccination vectors for eliciting an enhanced boosting immunization response. Methods of treatment and prevention of diseases using the vaccination schemes of the invention are also provided.

## Claims

### Claim 1

A method for inducing an enhanced immunological response against at least one antigen in a mammal, said method comprising the steps of:
inoculating the mammal with a first recombinant vector comprising a DNA vector and a gene encoding said antigen; and
inoculating the mammal with a boosting immunization with a second recombinant vector comprising a second DNA vector and the gene encoding said antigen.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the first recombinant vector comprises a recombinant vaccinia virus vector.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the first recombinant vector comprises a recombinant fowlpox virus vector.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the first recombinant vector comprises an adenovirus vector.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the recombinant vectors further comprise a gene encoding an immunostimulatory molecule.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the second recombinant vector comprises a recombinant vaccinia virus vector.

### Claim 7 (depends on 1)

The method according to claim 1 wherein the second recombinant vector comprises a recombinant fowlpox virus vector.

### Claim 8 (depends on 1)

The method according to claim 1 wherein the second recombinant vector comprises a recombinant adenovirus vector.

### Claim 9

The method of immunotherapy for treatment of a cancer patient, said method comprising the steps of:
immunizing said patient with an effective amount of a first recombinant vector comprising a first viral vector and a gene encoding a tumor-associated antigen; and
boosting said patient with an effective amount of a second recombinant vector comprising a second viral vector and the gene encoding the tumor-associated antigen.

### Claim 10 (depends on 9)

The method according to claim 9, wherein the tumor-associated antigen comprises gp100.

### Claim 11 (depends on 9)

The method according to claim 9, wherein the tumor-associated antigen comprises MART-1.

### Claim 12 (depends on 9)

The method according to claim 9, wherein the tumor-associated antigen comprises TRP-1.

### Claim 13 (depends on 9)

The method according to claim 9, wherein the tumor-associated antigen comprises TRP-2.

### Claim 14 (depends on 9)

The method according to claim 9, wherein the recombinant vectors further comprise a gene encoding an immunostimulatory molecule.

### Claim 15 (depends on 9)

The method according to claim 9, wherein the first viral vector comprises a vaccinia virus.

### Claim 16 (depends on 9)

The method according to claim 9, wherein the first viral vector comprises a fowlpox virus.

### Claim 17 (depends on 9)

The method according to claim 9, wherein the first viral vector comprises an adenovirus.

### Claim 18 (depends on 9)

The method according to claim 9, wherein the second viral vector comprises a vaccinia virus.

### Claim 19 (depends on 9)

The method according to claim 9, wherein the second viral vector comprises fowlpox virus.

### Claim 20 (depends on 9)

The method according to claim 9, wherein the second viral vector comprises an adenovirus.
